What Steminent Biotherapeutics does

Steminent Biotherapeutics (仲恩生醫科技股份有限公司) is a Taiwan-based, clinical-stage biopharmaceutical company developing allogeneic adipose-derived mesenchymal stem cell (ADMSC) therapies for rare neurodegenerative diseases. Its lead product, Stemchymal®, is a proprietary allogeneic ADMSC platform manufactured under PIC/S GMP standards and has completed two randomized, double-blind, placebo-controlled Phase 2 trials in Taiwan and Japan for spinocerebellar ataxia (SCA3 and SCA6), with additional pipeline activity in Huntington's disease. The company holds Orphan Regenerative Medicine Product designation from Japan's MHLW (2018), FDA Orphan Drug Designation, and is the first Taiwanese firm to receive MHLW Foreign Manufacturing Site certification for regenerative medicine products.

Steminent operates a dual-regulatory strategy targeting conditional/temporary drug approval in both Taiwan and Japan by 2027, parallel to a US Phase 2 clinical trial (IND) launched in 2026 via an investigator-initiated study at UCLA Health. Its commercial model combines direct product sales (Taiwan, future Japan via supply) with out-licensing to regional partners — REPROCELL holds exclusive Japan rights and submitted the PMDA application in June 2026 — alongside manufacturing collaborations with Terumo (intelligent cell expansion), Kohjin Bio (serum-free media), and Cyto-Facto (commercial scale-up). Pricing is not publicly disclosed.

The company is headquartered in Taipei with a wholly-owned US subsidiary (Steminent US, Inc.) in San Diego, employs 51–100 staff, and is listed on Taiwan's emerging board (興櫃, code 7729) while pursuing a full IPO. It is pre-revenue with the SCA market opportunity estimated at $11.5B (2023) to $20.7B (2033) across 350,000+ global patients and is targeting an initial 10% market share post-approval.

Name

Steminent Biotherapeutics

Legal name

仲恩生醫科技股份有限公司

Website

https://steminent.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

51–100 employees

Short description

Taiwan-based clinical-stage biotech developing Stemchymal®, an allogeneic adipose-derived mesenchymal stem cell therapy for rare neurodegenerative diseases including spinocerebellar ataxia. Pre-revenue, pursuing conditional approvals in Taiwan and Japan alongside a US Phase 2 trial.

Ownership category

akta.pro rank

Product category

Regenerative Medicine

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

Keywords

• Allogeneic stem cell therapy
• Mesenchymal stem cell therapy
• Rare disease therapeutics
• Regenerative medicine
• Cell therapy manufacturing

Headquarters

HQ city

Taipei

HQ country

Taiwan

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Stemchymal® Product Sales: Revenue from direct commercial sales of Stemchymal in Taiwan and Japan following regulatory approvals, with an initial target of capturing 10% market share in the spinocerebellar ataxia treatment market.
2. Licensing Royalties and Milestone Payments: Royalty and milestone revenue from international licensing agreements with partners including REPROCELL (Japan/Korea). Anticipated revenue streams include sales royalties, development milestones, and technology transfer fees.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels3 records

Core offering

Steminent Biotherapeutics develops and manufactures Stemchymal®, an allogeneic adipose-derived mesenchymal stem cell (ADMSC) therapy for rare neurodegenerative diseases, with the lead indication being spinocerebellar ataxia (SCA3 and SCA6). The product is manufactured under PIC/S GMP in Taiwan and is being commercialized through international licensing partners (REPROCELL for Japan) while direct US clinical development proceeds through academic medical centers such as UCLA Health.

Product overview

Steminent Biotherapeutics is a single-product biotechnology company focused on developing Stemchymal®, an allogeneic adipose-derived mesenchymal stem cell (ADMSC) therapy. The company's primary pipeline product targets rare neurodegenerative diseases, with spinocerebellar ataxia (SCA) as the lead indication. Stemchymal® has completed Phase 2 clinical trials in Taiwan and Japan, with regulatory submissions in progress for conditional approval in both markets.

Differentiator

Problem solved

Functional benefit

Brands

• Stemchymal®: Allogeneic adipose-derived mesenchymal stem cell (ADMSC) therapy product in clinical development for rare neurodegenerative diseases, most advanced indication being spinocerebellar ataxia (SCA).

Products and services

• Stemchymal® Stemchymal® is an allogeneic adipose-derived mesenchymal stem cell (ADMSC) therapy developed for treating rare neurodegenerative diseases, with the most advanced indication being spinocerebellar ataxia (SCA3 and SCA6). It is manufactured under PIC/S GMP standards in Taiwan and has completed Phase 2 clinical trials in both Taiwan and Japan demonstrating disease stabilization (treatment group SARA progression slowed to ~0.3–0.5/year vs. 1.4–1.6/year in untreated patients). The product holds FDA Orphan Drug Designation and Japan MHLW Orphan Regenerative Medicine Product designation, with regulatory submissions for conditional approval in Taiwan and Japan filed in 2025–2026.

Quantifiable outcome

• Treatment group disease progression rate slowed to ~0.3–0.5 SARA score increase per year vs. 1.4–1.6 SARA score increase in untreated SCA3 patients
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Five partnerships are on record, tiered core and minor.

• REPROCELL Inc.coreChannel Partner/ Reseller/ Distributor · 24 June 2026REPROCELL is the exclusive licensing and distribution partner for Stemchymal® in Japan. It submitted the manufacturing and marketing approval application to Japan's PMDA in June 2026 targeting spinocerebellar ataxia (SCA3 and SCA6). REPROCELL also submitted the Marketing Authorization Holder (MAH) manufacturing and sales license application to Kanagawa Prefecture in June 2026. This is Steminent's most advanced international commercial partnership.
• Terumo Blood and Cell TechnologiescoreStrategic or Co-development Partner · 13 May 2026Steminent signed a cooperation agreement with Terumo to jointly develop an intelligent cell expansion manufacturing process for Stemchymal®, leveraging Terumo's automated cell processing technology. This partnership aims to enhance manufacturing scalability and consistency for commercial production, and is central to Steminent's global manufacturing strategy.
• Cyto-FactocoreTechnology or Integration · 14 January 2026Steminent signed a Letter of Intent (LOI) with Japanese regenerative medicine company Cyto-Facto to collaborate on manufacturing scale-up for Stemchymal® in the Japanese market. Cyto-Facto brings expertise in Japanese regulatory compliance and commercial-scale cell therapy manufacturing.
• Kohjin Bio Co., Ltd.coreTechnology or Integration · 29 July 2025Steminent partnered with Japan's Kohjin Bio (Tokyo Stock Exchange: 177A) — a leading serum-free culture medium manufacturer with 40+ years of experience — to develop higher-specification serum-free cell culture technology for Stemchymal® manufacturing. The partnership, facilitated through Taiwan's Hongchi Industrial, aims to reduce batch variability, ensure quality consistency, and meet international regulatory standards for cell therapy production.
• UCLA Health / Dr. Susan PerlmanminorStrategic or Co-development Partner · 8 May 2025Dr. Susan Perlman, Clinical Professor of Neurology at UCLA and leading SCA expert, is conducting an investigator-initiated clinical trial (IND) of Stemchymal® in US SCA3 patients. This clinical collaboration provides first US clinical use data and serves as a gateway to the US market.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Mesoblast: Mesoblast is a commercial-stage cell therapy company developing allogeneic mesenchymal lineage cell therapies for rare inflammatory and neurodegenerative diseases. It is the closest direct comparator to Steminent in terms of MSC platform, orphan indication strategy, and clinical-stage pipeline.
• BrainStorm Cell Therapeutics: BrainStorm develops autologous MSC-based cell therapies (NurOwn) for neurodegenerative diseases including ALS and multiple sclerosis. Comparable to Steminent in targeting rare neurodegenerative diseases with a stem cell platform, though with autologous vs. allogeneic manufacturing.
• Pluristem Therapeutics: Pluristem develops allogeneic placental-derived cell therapies for rare diseases including hematologic and inflammatory conditions. Direct peer in allogeneic off-the-shelf cell therapy platform economics, GMP manufacturing, and orphan-drug regulatory strategy.
• Athersys: Athersys develops MultiStem, an allogeneic stem cell therapy for neurological, inflammatory, and cardiovascular indications. Comparable to Steminent in allogeneic cell therapy platform, clinical-stage development, and partnering-driven commercialization model.
• Capricor Therapeutics: Capricor develops cell therapy (CAP-1002, allogeneic cardiosphere-derived cells) for rare diseases including Duchenne muscular dystrophy. Direct peer in allogeneic cell therapy for rare diseases, regulatory orphan strategy, and late-stage clinical positioning.
• REPROCELL Inc. REPROCELL is a Japan-headquartered regenerative medicine company and Steminent's exclusive Japan distribution and MAH partner. Directly comparable as a Japanese cell therapy commercial-stage peer with regulatory expertise in PMDA regenerative medicine pathways.

Emerging players

• Larimar Therapeutics: Larimar Therapeutics develops a treatment for Friedreich's ataxia, a related hereditary ataxia. Comparable as a rare-disease-focused, indication-adjacent ataxia peer competing for similar specialist prescribers, KOL relationships, and patient advocacy infrastructure.
• Reata Pharmaceuticals (Biogen): Reata (now part of Biogen) developed Skyclarys (omaveloxolone), the first FDA-approved treatment for Friedreich's ataxia. Closest precedent for regulatory and commercial precedent in the ataxia space and a potential benchmark for Steminent's US commercial trajectory.

Broad incumbents

• Takeda Pharmaceutical: Takeda is Japan's largest pharmaceutical company with a global rare disease and cell therapy franchise. Comparable as a broad incumbent with strong Japan commercial infrastructure that may represent both a potential acquirer and competitive threat in Japanese cell therapy commercialization.
• Vertex Pharmaceuticals: Vertex is a global rare disease specialist with multiple orphan-drug launches. Comparable as a broad incumbent that pursues rare disease acquisitions and could be a potential strategic acquirer of Steminent's SCA franchise, particularly post-approval.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/Steminent

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Steminent Biotherapeutics